Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
Neurocrine Biosciences (NASDAQ:NBIX) has agreed to acquire Soleno Therapeutics (NASDAQ:SLNO) in an all-cash transaction valued at approximately $2.9 billion, it was announced on Monday. Under the terms of the agreement, Neurocrine will pay $53 per share for Soleno, representing a premium of about 34% over Soleno's closing stock price on April 2, 2026, and roughly 51% above its 30-day average. Shares of Soleno surged more than 32% to about $52 before Monday's opening bell, while Neurocrine stock was down 2% at $129. The acquisition is focused on Soleno's lead product, VYKAT XR (diazoxide choline), a treatment for hyperphagia associated with Prader-Willi syndrome. The therapy, approved by the US Food and Drug Administration in 2025, is the first medication specifically indicated for this condition, which is characterized by persistent hunger and can lead to serious health complications. Prader-Willi syndrome affects an estimated 10,000 people in the United States and involves a
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine to acquire Soleno in $2.9bn transaction [Yahoo! Finance]Yahoo! Finance
- Assessing Neurocrine Biosciences (NBIX) Valuation As Long Term Returns Outpace A Richer Earnings Multiple [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences (NBIX) had its price target raised by Citigroup Inc. from $204.00 to $242.00. They now have a "buy" rating on the stock.MarketBeat
- Neurocrine Biosciences (NBIX) had its price target raised by Canaccord Genuity Group Inc. from $164.00 to $200.00. They now have a "buy" rating on the stock.MarketBeat
- Neurocrine Biosciences (NBIX) had its price target raised by Wedbush from $151.00 to $166.00. They now have an "outperform" rating on the stock.MarketBeat
NBIX
Earnings
- 2/11/26 - Beat
NBIX
Sec Filings
- 4/6/26 - Form 8-K
- 3/27/26 - Form SCHEDULE
- 3/17/26 - Form 3
- NBIX's page on the SEC website